Acquisition by Singh Harvinder of 1179 shares of Integra LifeSciences subject to Rule 16b-3
| IART Stock | USD 21.71 0.45 2.03% |
Slightly above 61% of Integra LifeSciences' investor base is looking to short. The analysis of overall sentiment of trading Integra LifeSciences Holdings stock suggests that many investors are alarmed at this time. Integra LifeSciences' investing sentiment can be driven by a variety of factors including economic data, Integra LifeSciences' earnings reports, geopolitical events, and overall market trends.
Integra |
Filed transaction by Integra LifeSciences Holdings Officer: Evp & President, International. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Integra LifeSciences Fundamental Analysis
We analyze Integra LifeSciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integra LifeSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integra LifeSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Integra LifeSciences is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Integra LifeSciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Integra LifeSciences stock to make a market-neutral strategy. Peer analysis of Integra LifeSciences could also be used in its relative valuation, which is a method of valuing Integra LifeSciences by comparing valuation metrics with similar companies.
Peers
Integra LifeSciences Related Equities
| CNMD | CONMED | 0.98 | ||||
| ICUI | ICU Medical | 0.56 | ||||
| MMSI | Merit Medical | 0.89 | ||||
| HAE | Haemonetics | 2.37 |
Additional Tools for Integra Stock Analysis
When running Integra LifeSciences' price analysis, check to measure Integra LifeSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integra LifeSciences is operating at the current time. Most of Integra LifeSciences' value examination focuses on studying past and present price action to predict the probability of Integra LifeSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integra LifeSciences' price. Additionally, you may evaluate how the addition of Integra LifeSciences to your portfolios can decrease your overall portfolio volatility.